-
CPhI Annual Report reveals slow and discouraging trends in current drug pipelines
europeanpharmaceuticalreview
October 20, 2017
CPhI Worldwide report states the current drugs pipeline is discouraging and slowing simple manufacturing innovations…
-
EMA relocation will cause drug approval delays even in best case scenario, agency says
pharmafile
September 28, 2017
As a direct result of the UK’s referendum vote to leave the EU last year, the headquarters of the EMA, currently located in Canary Wharf, London, will be forced to relocate to another EU member state.
-
Antimicrobial test may combat drug resistance
europeanpharmaceuticalreview
September 27, 2017
Researchers have demonstrated a potential new tactic for rapidly determining whether an antibiotic combats a given infection, thus hastening effective medical treatment…
-
Speeding up drug discovery process with Artificial Intelligence
biospectrumasia
August 11, 2017
Experts say, Artificial Intelligence saves half the time and money needed for discovery of new drugs
-
Drugs taken before surgery may reduce metastatic recurrence
europeanpharmaceuticalreview
August 08, 2017
Researchers have identified a drug regimen administered prior to and after surgery that significantly reduces the risk of post-surgical cancer recurrence…
-
Tokyo Tech joins hands with Kawasaki City for drug discovery
biospectrumasia
August 08, 2017
The programme seeks to form an innovation ecosystem that bridges basic and fundamental research and the drug discovery business.
-
New injectable antiretroviral treatment for HIV patients
europeanpharmaceuticalreview
August 04, 2017
A phase II clinical trial has paved the way to the implantation of all-injectable antiretroviral therapies with a lower frequency of administration…
-
AstraZeneca's Priority Review good news provides reprieve
pharmafile
August 03, 2017
If there was a company that needed a series of good news stories this week, it was AstraZeneca. The blow of the Mystic trial was enough to have the company seeing stars, and its share value seeing the depths
-
Takeda, Tesaro ink strategic deal to co-develop and commercialize cancer drug
biospectrumasia
August 02, 2017
The deal, worth $340 mn gives Takeda exclusive commercial rights for all potential future niraparib indications in Japan
-
Researchers create a unique system for drug delivery
biospectrumasia
July 31, 2017
This technique increases the permeability of the skin by heating and removing the first skin layer.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
